Buprenorphine-Naloxone Cuts Nonfatal Overdose vs XR Naltrexone Post-Withdrawal
For pharmacists managing opioid use disorder transitions, this large target trial emulation quantifies real-world overdose differences between buprenorphine-naloxone and extended-release naltrexone that randomized trials were too small to detect.
Buprenorphine-naloxone reduces overdose risk more effectively than XR naltrexone.
Comparing buprenorphine-naloxone and extended-release naltrexone helps identify safer and more effective treatments for opioid use disorder and reduces risks such as overdose. Buprenorphine-naloxone showed a lower incidence of nonfatal opioid overdose (11.6%) compared to XR naltrexone (13.9%), with similar all-cause mortality rates at 24 weeks. This study provides evidence to prefer buprenorphine-naloxone over XR naltrexone for lowering overdose risk following opioid withdrawal, though both treatments show similar mortality outcomes. Buprenorphine-naloxone reduces the risk of nonfatal opioid overdoses compared to XR naltrexone post-withdrawal.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Hsu HE, Lodi S, Yan S, Bovell-Ammon BJ, Christine PJ, Tilhou AS, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR
Citation:Hsu HE, Lodi S, Yan S, et al. Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment. JAMA network open. 2026;9(7):e2623280. doi:10.1001/jamanetworkopen.2026.23280